Navigation Links
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29

Post Your Comments:
(Date:11/6/2009)...Kaiser Foundation Health Plan, Inc., Kaiser Founda...ported today a combined total operating revenue of... 2009, compared to $10.2 billion in the third quar...arter was $336 million, compared to $307 million i...g income was $233 million in the third quarter, co...
(Date:11/6/2009)...e/ -- America,s Specialty Medicines Companies (ASM...aller innovator pharmaceutical companies, today ex...Health Care for America Act," introduced by House ...fear that the cumulative effect of a host of provi...ing new medicines to market. ,, From required...
(Date:11/6/2009)...Call/ -- Virtual Health Technologies, Inc. (OTC Bu...ously confirmed Letter of Intent to sell all healt...gies, Inc (WNDM) is subject to final approval of ... ,, Shareholder Assurances ,, "We believe ...and cash realized from the transaction would benef...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 1Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 2Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 1FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 2FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 3FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 4FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 5FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 7FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 8
...rontiers Uses Novel Technology in Treatment of Chr...atients, CARLSBAD, Calif., Jan. 16 Ablation Fron...lment in the first ever U.S.,Investigational Devic...l,treatment of chronic atrial fibrillation (AF). A...FDA) to proceed with the pivotal phase of the,stud...
...t menu expanded through use of advanced LOCI(R) ch...nology, DEERFIELD, Ill., Jan. 16 Siemens Healthc...hed the LOCI(R) Folate,LOCI(R) B12, and LOCI(R) Fe...0 Intelligent Lab System, an ultra-integrated chem... to diagnose and monitor anemia in patients,and fu...
Other Medicine Technology:FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System 2Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System 3
(Date:11/7/2009)...e-USNewswire/ -- The American Medical Association ...alth at the Family Violence Prevention Fund, with ...s semi-annual policy-making meeting. The Citation...e AMA House of Delegates bestows on a non-physicia...n/prnh/20081209/AMALOGO ) ,, "Ms. James has w...
(Date:11/7/2009)...e-USNewswire/ -- Members of the AMA are trying a l...tion rescinding the AMA,s support of HR 3962. ,...ponsible to their PATIENTS, not the leadership of ...for the Association of American Physicians and Sur...r medical groups. ,, "If the AMA leadership ig...
(Date:11/7/2009)...wire-USNewswire/ -- The U.S. bishops November 7 ur...e for the Stupak-Ellsworth Amendment to the health...ptur-Dahlkemper-Lipinski-Smith Amendment will keep...and conscience protections in the Affordable Healt..., The letter was signed by Cardinal Justin Rigal...
(Date:11/7/2009)...lations Society of America (PRSA) will bestow the ...n, senior vice president of Brand Strategy, Commun...a ceremony at PRSA,s 2009 International Conference...College of Fellows is one of the profession,s high...SAGE, Fellow PRSA, and 2009 chair of the College o...
(Date:11/7/2009)... 23-25th marked the 12th annual tournament bringin...ttle against pediatric cancer. Stephen Updegraff,... for many years. , St. Pe...kend of October 23-25 marked the 12th annual tour...ighting the battle against pediatric cancer–...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3
...tion Extends Pace,s Laboratory Network to the West...vices, Inc.,(Pace Analytical) is pleased to announ...al Services, Inc., has purchased the assets of Lau...RCRA and CWA programs. For more than 100 years, La...
... women in Iowa are much more likely to suffer from...rparts, a new University of Iowa study shows. , I...unties, UI psychologist Lisa Segre found that 40 p...ent of new mothers with a household income of $80,...
...go hospital one of 5 percent in the nation to rece... American Nurses,Credentialing Center (ANCC) has a...designation for its excellence in nursing practice... standard,in nursing excellence., (Photo: http:/...
...s show patients live average of 4 years longer tha...ESDAY, Feb. 19 (HealthDay News) -- The lack of a c...ssive brain tumor respond better to a new treatmen.... A study of 25 people with the condition showed t...
...HILL, N.C., Feb. 19 With sales forces shrinking,a...ooling to the constant,demand for rep time, winnin...ore challenging. In response, leading pharma compa... to recent,research from pharmaceutical benchmarki...
...HERSBURG, MD February 19, 2008 A recent survey o...ined current attitudes and practices when caring f..., revealed that most respondents (70 percent) feel...was sponsored by MedImmune, Inc. , The incidence ...
Other Medicine News:Health News:Pace Analytical Services, Inc., Purchases Laucks Testing Laboratory, Inc. 2Health News:Study: low-income women more likely to suffer from postpartum depression 2Health News:Study: low-income women more likely to suffer from postpartum depression 3Health News:Sharp Memorial Hospital Achieves Highest Honor for Nursing Excellence 2Health News:Missing Chromosome Improves Response to Brain Tumor Treatment 2Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Neonatologists and pediatricians highlight progress and barriers to preemie care 2Health News:Neonatologists and pediatricians highlight progress and barriers to preemie care 3
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: